Exhibit
10.2


Consulting
Agreement 


Agreement
by and between Christine Ichim (“Consultant”) , a natural person whose address is at 12685 Campo Road, Spring Valley
CA 91978 and Regen Biopharma, Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304,
La Mesa, California 91942.


It is agreed as follows:


		1.	INVENTIONS



Consultant agrees that
she has been specifically hired by the Company to invent the following:


		a)	Cord Blood Small Molecule (“CBSM
                                         invention”)



		b)	Cancer Small Molecule Ligand
                                         Binding (“CSMLB Invention”)



		c)	Cancer Small Molecule Alpha
                                         helix Inhibitor (“CSMAI Invention”)



		d)	Cancer Small Molecule using
                                         170 Compound List (“CSM170 Invention”)



2. PATENT APPLICATIONS


Consultant
agrees to file with the United States Patent and Trademark Office provisional applications for patent and subsequent applications
for patent for all of the CBSM invention, the CSMLB Invention, the CSMAI Invention and the CSM170 Invention


3. ASSIGNMENT


Consultant assigns to
the Company 100% of her right, title, and interest in


		i)	CBSM invention



		ii)	CSMLB Invention



		iii)	CSMAI Invention



		iv)	CSM170 Invention



and
patent applications filed for the above (as well as such rights in any divisions, continuations in whole or part or substitute
applications) to Company .


Consultant
authorizes the United States Patent and Trademark Office and the equivalent authority of any nation to issue any Patents resulting
from applications for patent for any of the inventions which are the subject of this Agreement to the Company. The right, title
and interest is to be held and enjoyed by the Company and the Company's successors and assigns as fully and exclusively as it
would have been held and enjoyed by Consultant had this assignment not been made..


Consultant
further agrees to: (a) cooperate with Company in the prosecution of all applications for patent, provisional and nonprovisional,
and foreign counterparts; (b) execute, verify, acknowledge and deliver all such further papers, including patent applications
and instruments of transfer; and (c) perform such other acts as Company lawfully may request to obtain or maintain the Patent
for the inventions in any and all countries.


		4.	CONSIDERATION



		v)	As
                                         consideration for the invention, patent prosecution and assignment of all right, title
                                         and interest to CBSM invention Consultant shall be issued One Hundred Thousand Common
                                         Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars
                                         to be paid upon the filing with the United States patent and Trademark Office of a provisional
                                         applications for patent for the CBSM Invention



		vi)	As
                                         consideration for the invention, patent prosecution and assignment of all right, title
                                         and interest to CSMLB invention Consultant shall be issued One Hundred Thousand Common
                                         Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars
                                         to be paid upon the filing with the United States patent and Trademark Office of a provisional
                                         applications for patent for the CSMLB Invention



		vii)	As
                                         consideration for the invention, patent prosecution and assignment of all right, title
                                         and interest to CSMAI invention Consultant shall be issued One Hundred Thousand Common
                                         Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars
                                         to be paid upon the filing with the United States patent and Trademark Office of a provisional
                                         applications for patent for the CSMAI Invention



		viii)	As
                                         consideration for the invention, patent prosecution and assignment of all right, title
                                         and interest to CSM170 invention Consultant shall be issued One Hundred Thousand Common
                                         Shares of the Company and Three Thousand Dollars, such shares to be issued and dollars
                                         to be paid upon the filing with the United States patent and Trademark Office of a provisional
                                         applications for patent for the CSM170 Invention
	 	v.)	Consultant
                                         shall be entitled to royalties during the term of any patent granted for the CBSM invention,
                                         CSMLB invention ,CSMAI invention and CSM170 invention of 5% of Net Sales made by the
                                         Company of the CBSM invention, CSMLB invention ,CSMAI invention and CSM170 invention.
                                         Net Sales" means the monetary consideration actually received by Company for the
                                         transfer of the invention less any of the following items






(a)outbound
shipping, storage, packing and insurance expenses;


(b) distributor
discounts;


(c)
allowance for doubtful accounts or uncollectible accounts receivable;


(d) amounts repaid
or credited as a result of rejections, defects, or returns


(e) sales and
other excise taxes (excluding VAT), tariffs, export license fees and duties paid to a governmental entity


(f) sales commissions.


		5.	RESTRICTED SECURITIES ACKNOWLEDGMENT



Consultant
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities Act
of 1933, and shall contain the following restrictive legend:


“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”


		6.	SPECIFIC PERFORMANCE



Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available, Consultant acknowledges and agrees that Company may immediately
seek enforcement of this Agreement by means of specific performance or injunction, without any requirement to post a bond or other
security.


		7.	EXECUTION



This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.


		8.	ENTIRE AGREEMENT



This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.


		9.	SEVERABILITY



If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement


		10.	GOVERNING LAW, VENUE, WAIVER
                                         OF JURY TRIAL



All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.


IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.


 


Company


 


By/s/David R. Koos


____________


David R. Koos


Chairman & CEO


Regen Biopharma , Inc.


 


 


Consultant





By/s/Christine Ichim


_____________


Christine Ichim, PhD